SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

RESEARCH






 
 


Research Overview


The Division of Hematology/Oncology is actively advancing the understanding, diagnosis, and treatment of cancer through nationally-recognized basic, translational, clinical, and population-based research programs. The Division has enjoyed a long history of outstanding research support, with $9.2 million in direct funding in FY 2015. The University of Pittsburgh Cancer Institute (UPCI) serves as the hub for the Hematology/Oncology scientific and clinical research activities. UPCI is Western Pennsylvania’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is ranked 12th in NCI funding.  

Through our clinical research programs, our faculty are defining lifesaving approaches and accelerating the transformation of breakthroughs in their laboratories into clinical application for patients within the region and beyond. Clinical faculty are actively enrolling patients into clinical trials that investigate novel agents and combination regimens.  In FY15, Division faculty enrolled 1,230 patients into various therapeutic, non-therapeutic, and compassionate-use clinical trials, a 37% increase over FY14. 


Cancer Research

Within the Division, several members are internationally recognized for their leadership and expertise in various sold tumors. With the patient at the center of its mission, Division faculty strive to improve their understanding of the biological basis of cancer to develop new approaches for the prevention of cancer and to refine and redefine the ways in which patients are diagnosed and treated.


Hematology Research

The Division features a benign hematology section with physician-scientist and research investigators. This group is now one of the larger benign hematology programs in the United States. Thanks to recent growth, we expect grant funding and clinical trial accruals to increase significantly over the next few years. For example, we plan to develop a Benign Hematology Center of Excellence in collaboration with the Institute for Transfusion Medicine. This Center will offer comprehensive outpatient clinical services for the entire spectrum of benign hematologic disorders. In addition to clinical care, the Center will conduct state-of-the-art clinical and translational hematology research.